Our data suggest that, in routine practice, people with type 2 diabetes and initially poor glycaemic control have a similar risk of major macrovascular events (MI, acute coronary syndrome, stroke or death) in the medium term regardless of what type of insulin is started. Here, INS is linked to acute coronary syndrome.